SARS-CoV-2 Vaccines: Status Report

• Published in: Immunity (Cambridge, Mass.) Vol. 52; no. 4; pp. 583 - 589
• Main Authors: Amanat, Fatima, Krammer, Florian
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 14.04.2020; Elsevier Limited
• Subjects: Animals; Betacoronavirus - immunology; Betacoronavirus - pathogenicity; China; Clinical trials; Clinical Trials as Topic; Coronavirus - pathogenicity; Coronavirus Infections - epidemiology; Coronavirus Infections - prevention & control; Coronaviruses; COVID-19; COVID-19 Vaccines; Disease Models, Animal; Disease transmission; Drug Development; Fatalities; Genomes; Humans; Infections; Middle East respiratory syndrome; Morbidity; Pandemics; Pandemics - prevention & control; Pneumonia; Pneumonia, Viral - epidemiology; Pneumonia, Viral - prevention & control; Proteins; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Swine flu; Time Factors; Vaccine development; Vaccines; Viral diseases; Viral Vaccines - therapeutic use; Viruses; China; Italy; South Korea; Iran; United States > US; Spain
• ISSN: 1074-7613; 1097-4180; 1097-4180
• DOI: 10.1016/j.immuni.2020.03.007

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population. Amanat and Krammer discuss therapeutic and prophylactic interventions for SARS-CoV-2, the causal agent of COVID-19, with a focus on vaccine development and its challenges.